- Home
- CARS vs TERN Comparison
CARS vs TERN Comparison
Compare CARS & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- TERN
- Stock Information
- Founded
- CARS 1998
- TERN 2017
- Country
- CARS United States
- TERN United States
- Employees
- CARS N/A
- TERN N/A
- Industry
- CARS Motor Vehicles
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- CARS Consumer Discretionary
- TERN Health Care
- Exchange
- CARS Nasdaq
- TERN Nasdaq
- Market Cap
- CARS 649.5M
- TERN 710.6M
- IPO Year
- CARS 2017
- TERN 2021
- Fundamental
- Price
- CARS $11.41
- TERN $7.93
- Analyst Decision
- CARS Strong Buy
- TERN Buy
- Analyst Count
- CARS 5
- TERN 7
- Target Price
- CARS $17.90
- TERN $13.99
- AVG Volume (30 Days)
- CARS 980.3K
- TERN 1.5M
- Earning Date
- CARS 11-06-2025
- TERN 11-11-2025
- Dividend Yield
- CARS N/A
- TERN N/A
- EPS Growth
- CARS 69.36
- TERN N/A
- EPS
- CARS 0.63
- TERN N/A
- Revenue
- CARS $717,845,000.00
- TERN N/A
- Revenue This Year
- CARS $2.52
- TERN N/A
- Revenue Next Year
- CARS $3.00
- TERN N/A
- P/E Ratio
- CARS $17.92
- TERN N/A
- Revenue Growth
- CARS 0.68
- TERN N/A
- 52 Week Low
- CARS $9.56
- TERN $1.87
- 52 Week High
- CARS $20.47
- TERN $9.03
- Technical
- Relative Strength Index (RSI)
- CARS 49.52
- TERN 50.27
- Support Level
- CARS $10.43
- TERN $7.12
- Resistance Level
- CARS $10.85
- TERN $8.77
- Average True Range (ATR)
- CARS 0.45
- TERN 0.55
- MACD
- CARS 0.12
- TERN -0.11
- Stochastic Oscillator
- CARS 74.19
- TERN 46.17
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.